Skip to content

ScaiVision: our software platform

At the core of our company is Scailyte’s best-in-class analytical platform ScaiVision™. It unravels hidden secrets of complex single-cell multiomics data to extract composite biomarkers associated with different cell populations. Using a convolutional neural network, ScaiVision automatically learns molecular patterns associated with relevant clinical outcomes. These signatures can then be applied to classify new samples.

Key Benefits of ScaiVision

  • Entirely agnostic to indications of interest
  • Data augmentation enables the identification of accurate signatures from a limited number of samples
  • Fast and scalable analysis of datasets of up to hundreds of millions of cells
  • Retains single-cell resolution throughout the interpretation stage & calculates the clinical endpoint-associated score for every single cell
  • Flexible integration of multiomics and clinical data (scRNA-seq, CyTOF, CITE-seq, etc)

ScaiVision analysis workflow

ScaiVision® performs best-in-class at sample class prediction


We help drug developers increase the success rate of their products and speed up their R&D cycle by:

  • analysing the MoA of drug candidates on a single-cell and multiomics level
  • identifying predictive markers of response for patient stratification and smarter clinical trial design
  • finding predictive markers of toxicity for improved patient management
  • co-developing a companion diagnostic assay


  • Mass cytometry (CyTOF)
  • Single-cell RNA-seq
  • High-dimensional flow cytometry
  • CITE-seq
  • TCR / BCR-seq
Helping you speed up your therapy development and increase your success rate